You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
諾輝健康攜手愛康集團首次發佈《2021版北京百萬城市人羣健康報吿-精準醫療結直腸癌專項報吿》
格隆匯 12-16 10:04
格隆匯12月16日丨諾輝健康攜手愛康集團於12月15日首次發佈以城市為單位的《2021版北京百萬城市人羣健康報吿-精準醫療結直腸癌專項報吿》。諾輝健康旗下結直腸癌早篩產品常衞清採用多靶點糞便FIT-DNA檢測技術,於2020年11月獲批國家藥品監督管理局(NMPA)首個且目前唯一癌症早篩產品註冊證,適用於40-74歲結直腸癌高風險人羣的篩查。經國內首個且目前唯一癌症早篩大規模前瞻性多中心註冊臨牀試驗驗證,常衞清對於結直腸癌的檢測靈敏度為95.5%;對於進展期腺瘤的檢測靈敏度為63.5%,對結直腸癌的陰性預測值高達99.6%,可以最大程度避免漏檢並有效發現結直腸癌癌前病變。此次報吿的結直腸癌篩查結果顯示,常衞清檢測陽性率為9.06%,較去年有明顯上升。據2020年白皮書,北京愛康體檢人羣中常衞清檢測陽性率為8.78%。相比於2020年,常衞清陽性且腸鏡下檢出異常中癌前病變的比例從73.53%上升到77.31%。常衞清的使用顯著提升了陽性受檢者完成腸鏡檢查的依從率,極大推動了高風險人羣接受結直腸癌篩查。北京市常衞清陽性受檢者完成腸鏡檢查的依從度從2020年的29.38%提高到48.06%。同期,全國北上廣深蘇魯川浙8省市的腸鏡依從率提高到48.85%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account